{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.84","upperLimit":"3.71","value":"3.71"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"description":"TTR was defined as the time from the date of first dose to the date of initial documentation of a response (PR or better) for responders. PR: \\>=50% reduction of serum IgM from baseline, with reduction in lymphadenopathy/splenomegaly if present at baseline. VGPR: \\>=90% reduction of serum IgM from baseline or normal serum IgM values, with reduction in lymphadenopathy/splenomegaly if present at baseline.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with relapsed or refractory waldenstrom's macroglobulinemia received ibrutinib 420 milligrams (mg) (3\\*140 mg capsules) orally once daily from Day 1 of Week 1 until disease progression, unacceptable toxicity, whichever occurs first.","id":"OG000","title":"Ibrutinib 420 mg"}],"paramType":"MEDIAN","populationDescription":"Analysis population included responders in all treated analysis set who achieved PR or better.","reportingStatus":"POSTED","timeFrame":"From start of the treatment up to first documentation of PR or better (Day 1 up to 49.3 months)","title":"Time to Response (TTR)","type":"SECONDARY","unitOfMeasure":"Months"}